Foresite Capital

Last updated
Foresite Capital
Company type Private company
Industry Venture capital, growth equity
Founded2011;13 years ago (2011)
FounderJim Tananbaum
Headquarters
San Francisco
,
United States
Area served
Worldwide
Key people
Jim Tananbaum (CEO)
Website www.foresitecapital.com

Foresite Capital (Foresite) is an American, multi-stage healthcare and life sciences investment firm headquartered in Los Angeles, and with offices in The San Francisco Bay Area and New York City. [1] [2] As of June 2024, the company had raised six primary funds: Foresite Capital Fund I, II, III, IV, V and VI. [1] [3]

Contents

History

Foresite Capital was founded in 2011 by Jim Tananbaum. [4] [5] [6] Foresite Capital raised its $100 million Fund I in 2013. [7] [8] [6] In 2014, Foresite Capital closed Foresite Capital Fund II, a $300 million fund. [9] Foresite Capital Fund III, a $450 million fund, was closed in July 2015. [9] Foresite Capital Fund IV, a $668 million fund, closed in March 2018. [10] Foresite Capital Fund V, a $776 million fund and its associated opportunity fund closed in February 2021. [11] Foresite Labs Fund I, a $173 million fund, closed in January 2022. Foresite Capital Fund VI, a $900 million fund, closed in May 2024. [12]

Investments

Foresite Capital funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016. [13] [14] Foresite Capital has invested in companies such as Acceleron Pharma, Aimmune, Alumis, ALX Oncology, Aerie Pharmaceuticals, [15] Ascendis, Blueprint Medicines, CG Oncology, Color Genomics, Cue Health, Cytokinetics, DNAnexus,[ citation needed ] Editas Medicine, [16] Eikon Therapeutics, Element Biosciences, [17] Epizyme, [1] Evonetix, Intarcia Therapeutics, [18] [19] Inscripta, [20] Immunomedics, [21] [22] Intellia Therapeutics,[ citation needed ] Juno Therapeutics, [23] Karyopharm, Keryx, Kura Oncology, Keros Therapeutics, Latigo, Maze Therapeutics, MyoKardia, MyOme, Natera, [21] Nurix, Olema Oncology, Orexigen, [24] Pacific Biosciences, [25] Peloton Therapeutics, Pharvaris, MindStrong Health, Quantum-SI, Relay Therapeutics, [26] Insitro, [27] HealthVerity, Turning Point Therapeutics, Portola Pharmaceuticals, Universal American, Xaira Therapeutics, Xencor, RayThera, and WaveTech, in addition to 10x Genomics. [28]

Leadership

Foresite Capital is led by Midas List honoree Jim Tananbaum along with managing directors Vikram Bajaj, [29] Dorothy Margolskee, Michael Rome, Dennis Ryan, and Hadi Tabbaa. [30] [31]

Related Research Articles

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">New Enterprise Associates</span> American Venture Capital firm

New Enterprise Associates (NEA) is an American-based venture capital firm. NEA focuses investment stages ranging from seed stage through growth stage across an array of industry sectors. With over $25 billion in committed capital, NEA is one of the world's largest venture capital firms.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas raised its thirteenth fund totaling $450 million in March 2022, after raising its Opportunity Fund II totaling $300 million in September 2021.

DNAnexus is an American company that provides a cloud-based data analysis and management platform for DNA sequence data. It is based in Mountain View, California, and was founded in 2009 by Stanford University professors Serafim Batzoglou and Arend Sidow and Stanford computer scientist Andreas Sundquist.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Francesco De Rubertis is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016. Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.

Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.

Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 (Plenity) for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.

<span class="mw-page-title-main">BoxGroup</span> American investment fund company

BoxGroup is an investment fund company based in New York City. The company was founded in 2007 by David Tisch, grandson of entrepreneurs Laurence A. Tisch, and Adam Rothenberg.

<span class="mw-page-title-main">Pitango</span> Israeli venture capital fund

Pitango VC, established in 1993, is Israel's largest venture capital fund with over $2.8 billion under management. Pitango VC invests through three dedicated funds, Pitango First, Pitango HealthTech, and Pitango Growth. Pitango invests in startups around the world, in domains such as Vertical SaaS, Digital Health, Deep Tech, FinTech & InsureTech, Devops, Generative AI, Web3, and FoodTech.

<span class="mw-page-title-main">Gregory L. Verdine</span> American chemical biologist

Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.

<span class="mw-page-title-main">Fortress Biotech</span>

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Silverton Partners is an early-stage venture capital firm headquartered in Austin, Texas.

<span class="mw-page-title-main">Section 32 (company)</span> American venture capital firm

Section 32 is a California-based venture fund founded by Google Ventures founder, Bill Maris. Section 32 funds technology, biotechnology, healthcare and life sciences companies and has approximately $1 billion under management.

IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.

Sophia Genetics SA is a data-driven medicine software company with headquarters in Lausanne, Switzerland and Boston, Massachusetts. It provides genomic and radiomic analysis for hospitals, laboratories, and biopharma institutions. The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017. The company went public on the Nasdaq in 2021, floating at $1.1B.

PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Oxford Sciences Enterprises is an early-stage venture capital firm with over $800M in AUM based in Oxford, UK. It operates in partnership with the University of Oxford, as the university's preferred investor, several prominent financiers back the firm, including Google Ventures, Sequoia Capital, Tencent, Huawei and Invesco. The firm uses academic research from the university's science departments to form commercial businesses, also known as spin-outs.

References

  1. 1 2 3 David Holley (29 July 2015). "Foresite Capital Keeps Late-Stage Healthcare Focus With $450M Third Fund". Xconomy. Retrieved 20 May 2017.
  2. ↑ Brian Gormley (31 January 2013). "Growth-Equity Firm Foresite Capital Raises $100M for Debut Health-Care Fund". Wall Street Journal. Retrieved 20 May 2017.
  3. ↑ "Foresite Capital launchew new venture capital fund worth $668 million". Biospace. Retrieved 21 June 2019.
  4. ↑ Damian Garde (29 July 2015). "Foresite Capital reloads with a $450M biotech venture fund". Fierce Biotech. Retrieved 20 May 2017.
  5. ↑ "Foresite Capital raises $100M to invest in late-stage healthcare companies". San Francisco Business Times. 31 January 2013. Retrieved 20 May 2017.
  6. 1 2 Eric Blattberg (1 April 2014). "Health care venture firm Foresite Capital closes $300M fund". Venture Beat. Retrieved 20 May 2017.
  7. ↑ Ben Fidler (6 November 2013). "Karyopharm Prices Upsized IPO at $16 Per Share, Begins Trading Today". Xconomy. Retrieved 20 May 2017.
  8. ↑ Luke Timmerman (31 January 2013). "Foresite Capital Closes $100M Fund for Late-Stage Biotechs". Xconomy. Retrieved 20 May 2017.
  9. 1 2 Damian Gards (1 April 2014). "Foresite banks $300M to bet on late-stage biotechs". Fierce Biotech. Retrieved 20 May 2017.
  10. ↑ "Venture fund Foresite Capital raises largest-ever $668m fund". Mass Device. 4 May 2018. Retrieved 19 June 2019.
  11. ↑ "Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth". TechCrunch. Retrieved 2021-03-16.
  12. ↑ "VC's new $900 million fund looks to push tech-biotech innovation". The Business Journals. Retrieved 12 June 2024.
  13. ↑ Nick Paul Taylor (21 March 2016). "10X Genomics scoops another $55M to fuel commercialization of long-read tech". Fierce Biotech. Retrieved 20 May 2017.
  14. ↑ Alex Lash (12 January 2015). "10X Genomics Emerges With $80M and Toaster-Sized Sequencer Upgrade". Xconomy. Retrieved 20 May 2017.
  15. ↑ Ed Lin (14 October 2016). "Aerie Stock Hits Record High, Holder Sells $2 Million". Barrons. Retrieved 20 May 2017.
  16. ↑ "Foresite Capital - Massinvestor Venture Capital and Private Equity Database". massinvestordatabase.com. Retrieved 2019-02-27.
  17. ↑ "Element Biosciences Lands $15M to Develop New Genetic Analysis Tools". Xconomy. Retrieved 21 June 2019.
  18. ↑ Dan Primack (15 September 2016). "Diabetes 'Unicorn' Raises Final VC Round Before IPO". Fortune. Retrieved 20 May 2017.
  19. ↑ "Here's who stands to gain from Intarcia's success with a type 2 diabetes pump". Boston Business Journal. 2 October 2014. Retrieved 20 May 2017.
  20. ↑ "Muse Bio Closes $23M Series B Financing Round". Genome Web. Retrieved 20 May 2017.
  21. 1 2 "FORESITE CAPITAL MANAGEMENT III, LLC Institutional Portfolio". NASDAQ.com. Retrieved 2019-05-02.
  22. ↑ "Intarcia Therapeutics Venture Capital and Private Equity Financings". www.vcnewsdaily.com. Retrieved 2019-02-27.
  23. ↑ "Foresite Capital reloads with a $450M biotech venture fund". FierceBiotech. Retrieved 2019-05-02.
  24. ↑ "Xconomy: Foresite Capital Reloads With New $300M Late-Stage Biotech Fund". Xconomy. 2014-04-01. Retrieved 2019-05-14.
  25. ↑ Timmerman, Luke. "Stealthy 10X Genomics Raises $55.5M To Beef Up DNA Sequencing". Forbes. Retrieved 2019-05-14.
  26. ↑ "Relay Therapeutics hits VC jackpot with $400M series C round for protein-motion drug discovery". Med City News. 20 December 2018. Retrieved 19 June 2019.
  27. ↑ "Backed by big-name VCs, this startup is turning machine learning on drug discovery". The Business Journals. Retrieved 19 June 2019.
  28. ↑ "Foresite Capital Management Iv, Llc - Latest 13F Holdings - Fintel.io". fintel.io. Retrieved 2019-05-14.
  29. ↑ "Heir Apparent at Carnegie Corp. Exits for Biotech Venture Firm". Institutional Investor. 14 October 2020. Retrieved 18 December 2020.
  30. ↑ "A life sciences firm run by a top VC and a cofounder of Alphabet's life sciences arm, just raised its biggest fund yet". TechCrunch. 5 May 2018. Retrieved 19 June 2019.
  31. ↑ "Nine VCs who matter but you never read about". Knect365. Retrieved 19 June 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.